glutathione persulfide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: glutathione persulfide
• 英文别名: S-Sulfanylglutathione；(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-(disulfanyl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
• 化学式: C₁₀H₁₇N₃O₆S₂
• 分子量: 339.393
• InChiKey: QBOLVLBSUGJHGB-WDSKDSINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.1
• 重原子数：
  21
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  185
• 氢给体数：
  6
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  L-谷胱甘肽 (氧化型) 在 sodium sulfide 、 氢气 作用下， 以 aq. phosphate buffer 为溶剂， 生成 谷胱甘肽 、 glutathione persulfide
  参考文献：
  名称：

  结构和生化分析表明细菌过硫化物双加氧酶-硫氰酸酶融合蛋白在硫同化中发挥作用。

  摘要：

  硫化氢 (H2S) 是一种信号分子，浓度升高时有毒。在真核生物中，它通过线粒体硫化物氧化途径被清除，该途径包括硫化物醌氧化还原酶、过硫化物双加氧酶（PDO）、硫氰酸酶和亚硫酸盐氧化酶，并将H2S转化为硫代硫酸盐和硫酸盐。某些细菌中存在含有 PDO 的非血红素铁和硫醇硫转移酶硫醇硫酶之间的天然融合。然而，人们对 PDO-硫氰酸酶融合 (PRF) 蛋白在硫代谢中的作用知之甚少。在此，我们报告了革兰氏阴性内生细菌伯克霍尔德氏菌 PRF 的动力学特性和晶体结构。野生型 PRF 和硫转移酶灭活的 C314S 突变体（含和不含谷胱甘肽）的晶体结构在 1.8、2.4 和分辨率分别为 2.7 Å。我们发现这两个活动地点距离很远，并且没有显示出直接通信的证据。B. phytofirmans PRF 表现出强大的 PDO 活性，并优先催化硫代硫酸盐向亚硫酸盐和谷胱甘肽过硫化物的方向转移；仅在有限的周转条件下才

  DOI：

  10.1074/jbc.m117.790170

文献信息

• Iterative synthetic strategies and gene deletant experiments enable the first identification of polysulfides in <i>Saccharomyces cerevisiae</i>
  作者：Lisa I. Pilkington、Rebecca C. Deed、Katie Parish-Virtue、Chien-Wei Huang、Michelle E. Walker、Vladimir Jiranek、David Barker、Bruno Fedrizzi

  DOI：10.1039/c9cc03020d

  日期：——

  Polysulfides, potential signalling molecules, were synthesised and then found and explored for the first time in yeast.

  聚硫化物，潜在的信号分子，首次在酵母中被合成、发现并探索。
• CHALLENGE TEST FOR DIAGNOSING SUBTYPE OF AUTISM SPECTRUM DISEASE
  申请人：Stalicla S.A.

  公开号：EP3479845A1

  公开（公告）日：2019-05-08

  The present invention is directed to a method of identifying autism spectrum disorder (ASD) subtype 1 patients, wherein the method comprises: administering an Nrf2-activator to an ASD patient previously diagnosed with ASD or a subject displaying clinical signs of ASD, and identifying the ASD patient as an ASD subtype 1 patient if the patient shows a negative response after administration of the Nrf2-activator. Likewise, the present invention is directed to an Nrf2-activator for use in identifying autism spectrum disorder (ASD) subtype 1 patients, wherein the Nrf2-activator is administered to a subject, wherein the subject is a patient previously diagnosed with ASD or a subject displaying clinical signs of ASD and wherein an ASD subtype 1 patient is identified by a negative response.

  本发明涉及一种鉴别自闭症谱系障碍（ASD）亚型1患者的方法，其中该方法包括：向先前诊断为ASD的ASD患者或显示ASD临床症状的受试者施用Nrf2-激活剂，如果患者在施用Nrf2-激活剂后显示阴性反应，则将该ASD患者鉴别为ASD亚型1患者。同样，本发明涉及一种用于鉴定自闭症谱系障碍（ASD）亚型1患者的Nrf2-激活剂，其中将Nrf2-激活剂施用给受试者，受试者是先前诊断为ASD的患者或显示ASD临床症状的受试者，并且通过阴性反应鉴定ASD亚型1患者。
• Compositions and methods for recovery of stranded gas and oil
  申请人：CALYSTA, INC.

  公开号：US10273446B2

  公开（公告）日：2019-04-30

  The present disclosure provides compositions and methods for using recombinant C1 metabolizing microorganisms capable of metabolizing sulfur containing compounds and other contaminants to biologically convert sour or acidic natural gas into high-value molecules, and to allow recovery of stranded oil.

  本公开提供了使用重组 C1 代谢微生物的组合物和方法，这些微生物能够代谢含硫化合物和其他污染物，以生物方式将酸性或酸性天然气转化为高价值分子，并实现搁浅石油的回收。
• Method of identifying ASD phenotype 1 patients
  申请人：Stalicla S.A.

  公开号：US11364311B2

  公开（公告）日：2022-06-21

  The present invention is directed to a method of identifying autism spectrum disorder (ASD) phenotype 1 patients, wherein the method comprises: administering an Nrf2-activator to an ASD patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD, and identifying the ASD patient as an ASD phenotype 1 patient if the patient shows a negative response after administration of the Nrf2-activator. Likewise, the present invention is directed to a method for classifying autism spectrum disorder (ASD) phenotype 1 patients, the method comprising: administering an Nrf2-activator to a subject, and observing if the subject shows a negative response after administration of the Nrf2-activator, in which the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD and in which the negative response supports classification of the subject as an ASD phenotype 1 patient.

  本发明涉及一种鉴定自闭症谱系障碍（ASD）表型1患者的方法，其中该方法包括：给先前诊断为特发性ASD的ASD患者或显示ASD临床症状的受试者施用Nrf2-激活剂，如果患者在施用Nrf2-激活剂后显示出负反应，则将该ASD患者鉴定为ASD表型1患者。同样，本发明还涉及一种对自闭症谱系障碍（ASD）表型1患者进行分类的方法，该方法包括：给受试者施用Nrf2-激活剂，观察受试者在施用Nrf2-激活剂后是否表现出阴性反应，其中受试者是先前诊断为特发性ASD的患者或表现出ASD临床症状的受试者，阴性反应支持将受试者分类为ASD表型1患者。
• Challenge test for diagnosing subtypes of ASD
  申请人：Stalicla S.A.

  公开号：US11357871B2

  公开（公告）日：2022-06-14

  The present invention is directed to a method for differentiating between ASD phenotype 1, phenotype 2 and other ASD patients, wherein the method comprises: administering an Nrf2-activator to a subject, and identifying the subject as an ASD phenotype 1 patient if the subject shows a negative response, as a phenotype 2 patient if he shows a positive response and as another ASD patient if he does not show a positive nor a negative response, wherein the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD. Likewise, the present invention is directed to an Nrf2-activator for use in differentiating between autism spectrum disorder (ASD) phenotype 1 patients, phenotype 2 patients and other ASD patients, wherein the Nrf2-activator is administered to a subject, wherein a phenotype 1 patient is identified by a negative response, a phenotype 2 patient is identified by a positive response and other ASD patients are identified by the absence of a positive and a negative wherein the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD.

  本发明涉及一种用于区分ASD表型1、表型2和其他ASD患者的方法，其中该方法包括：给受试者施用Nrf2-激活剂，如果受试者表现出阴性反应，则将其鉴定为ASD表型1患者；如果受试者表现出阳性反应，则将其鉴定为表型2患者；如果受试者既未表现出阳性反应也未表现出阴性反应，则将其鉴定为其他ASD患者，其中受试者是先前被诊断为特发性ASD的患者或表现出ASD临床症状的受试者。同样，本发明涉及一种用于区分自闭症谱系障碍（ASD）表型1患者、表型2患者和其他ASD患者的Nrf2-激活剂，其中将Nrf2-激活剂施用于受试者，表型1患者通过阴性反应确定，表型2患者通过阳性反应确定，其他ASD患者通过不显示阳性和阴性反应确定，其中受试者是先前诊断为特发性ASD的患者或显示ASD临床症状的受试者。